Conditions · Pancreatic cancer
Pancreatic cancer frontier treatment options
KRAS-targeted agents, vaccine programs and DDR-directed therapy each publish specific mutation requirements. Matching against them narrows hundreds of listings to the handful worth calling.
Open options now (1135 open studies; showing 30)
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
RP-001
- TRIALNARECRUITING
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
BGT007H Cell Injection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Biospecimen Collection · Computed Tomography · Core Biopsy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
VB15010 — 1 site
- TRIALPHASE2RECRUITING
EUS-RFA PANCARDINAL-1 Trial
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) · Neoadjuvant Chemotherapy (NAC) — 1 site
- TRIALEARLY_PHASE1RECRUITING
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
ES502 Injection — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Nogapendekin Alfa Inbakicept (N803) · Sotevtamab · Zabadinostat (CXD101)
- TRIALNARECRUITING
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Palliative radiotherapy — 7 sites
- TRIALNARECRUITING
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
Daily Adaptive External Beam Radiation Therapy — 3 sites
- TRIALPHASE2RECRUITING
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Folfirinox — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
CD318-CAR-T cells
- TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine · Nab paclitaxel · Erlotinib — 1 site
- TRIALNANOT_YET_RECRUITING
Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer
Thermal Ablation · Chemotherapy
- TRIALNARECRUITING
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
Electronic Health Record Review · Smartphone Application-based Intervention · Survey Administration — 1 site
- TRIALPHASE3RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Ferric carboxymaltose · Placebo — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
Vitmain C plus herbal medicine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Carbon Nanoparticle-Loaded Iron [CNSI-Fe] · Carbon Nanoparticle-Loaded Iron — 9 sites
- TRIALNARECRUITING
Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain
transdiscal splanchnic neurolysis · paravertebral splanchnic neurolysis — 1 site
- TRIALPHASE2RECRUITING
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Low-dose Radiotherapy · Pucotenlimab · AG regimen — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
HLX43 DOSE 1 (2.5 mg/kg) · HLX43 DOSE 2 (3.0 mg/kg)
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALNARECRUITING
Target-specific immunoPET Imaging of Digestive System Carcinoma
[68Ga]Ga-DOTA-H2D3 · [18F]F-RESCA-RB14 · [68Ga]Ga-NOTA-T4 — 1 site
- TRIALNARECRUITING
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
NGS sequencing of mutations selected based on sequencing of primary tumors — 1 site
- TRIALNANOT_YET_RECRUITING
SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent
Standard Informed Consent · Multimedia Video - Based Informed Consent — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
[68Ga]Ga-DPI-4452 · [177Lu]Lu-DPI-4452 — 10 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
Adebrelimab · mRNA tumor vaccines — 1 site
- TRIALNARECRUITING
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Later-line therapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Directional Brachytherapy Source Implant — 6 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Narrow by phase or treatment type
By state in the United States
By country
Each country page filters the live registry to listed sites in that country and links to the relevant official national or regional registry for additional local discovery.
Common questions
- How does Trial0 find Pancreatic cancer options?
- Every list on this page is a live query of ClinicalTrials.gov (API v2) for open interventional trials and expanded-access programs, refreshed at most hourly. Nothing is hand-curated or cached beyond that window.
- Does a match mean the patient is eligible?
- No. Structured registry fields (age, sex, status, phase) give firm matched/not-matched states; free-text criteria can only be checked for mentions, which are signposts to verify with the site. Only the trial site can determine actual eligibility.
- What does the verified site data mean?
- Registry recruiting status is often stale. Trial0 separately records first-hand observations — whether a specific site is really recruiting and whether the investigator accepts outside referrals — each stamped with the date it was verified.
- What does access help cost?
- The eligibility map and new-trial alerts are free. Pro is $49/month or £49/month and covers contact research, draft preparation and approval-first outreach. Trial0 never takes a commission from a provider.
How to use this Pancreatic cancer trial page
This page is refreshed from live registry data and shows currently open interventional studies and expanded-access programmes. Trial records are leads, not a clinical recommendation.
Use the full matcher to add age, treatment history, biomarkers and a location. It labels published criteria honestly: a mention in free text is a prompt to verify, not a finding of eligibility.
Free alerts help you notice new registry entries. Pro can research a contact and prepare outreach, but Trial0 asks for approval before contacting each trial.
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Data refreshed at most every 1 hour(s).